


Antiplatelet Therapy After ACS: Once size does not fit all

Webinar and virtual round table discussion with Prof. Dr. Marco Valgimigli, Prof. Dr. Roxana Mehran and Prof. Dr. *to be confirmed* (moderation)



Tuesday
7.12.



17-18h
live-
online



EduCardio.ch

Antiplatelet therapy represents the principal treatment strategy for Acute Coronary Syndrome (ACS), along with timely revascularization when indicated¹. The optimal type and duration of the antiplatelet therapy can, however, remain a challenge.

In this webinar, Prof. Valgimigli and Prof. Mehran will present the latest evidence and guidelines and discuss their implication for clinical practice.

- **Prof. Dr. Roxana Mehran**, Director of Interventional Cardiovascular Research and Clinical Trials at the Zena and Michael A. Wiener Cardiovascular Institute at Mount Sinai School of Medicine, New York, USA
- **Prof. Dr. Marco Valgimigli**, deputy chief Interventional Cardiology, Cardiocentro Ticino, Lugano, CH
- **Prof. Dr. to be confirmed**, Chief xxx at the Centre Hospitalier Universitaire Vaudois and the University of Lausanne, CH

To follow the live webinar, please first register at <https://www.educardio.ch>.
The webinar can be found under “LIVE” events



CME credit requested (SGK). This webinar takes place thanks to the kind support of AstraZeneca and Medtronic.

1. Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, Khalid U. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021 Apr 20;325(15):1545-1555.